Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Employment Decrease Among Patients Newly Diagnosed with Early Versus Late-STAGE Cancers in the US

Speaker(s)

Cong Z1, Tran O2, Nelson J2, Silver M2, Chung KC1
1GRAIL, LLC, a subsidiary of Illumina, Inc., Menlo Park, CA, USA, 2IBM Watson Health, Cambridge, MA, USA

OBJECTIVES: The total economic burden of cancer reflects direct and indirect costs, including productivity loss due to employment change, absenteeism, presenteeism, and premature death of patients and impacts on caregivers. This study estimated the magnitude of employment decrease among employees newly diagnosed with early (non-metastatic) versus late-stage (metastatic) cancer in the US.

METHODS: IBM MarketScan® Commercial Claims and Encounters Database was used to identify employees aged 18–64 and newly diagnosed with any cancer from 2009-2019. Employment decrease was defined as changing from “active full time” to “part time” or “quit job”, or from “part time” to “quit job” after cancer diagnoses. Baseline characteristics, proportions of employees with employment decrease during months 1-3, 4-6, and 7-12 after cancer diagnosis, and time to employment decrease, were summarized descriptively, stratifying by metastatic status at diagnosis.

RESULTS: 1,226,830 employees newly diagnosed with cancer were identified (mean age: 54 years, female: 52%, metastatic: 9.2%). Mean duration of follow up was shorter for employees with metastatic (20.9 [SD 22.1] months) vs. non-metastatic (31.7 [27.6] months) (p<0.001) disease. During the month prior to cancer diagnoses, 53% of metastatic and 55% non-metastatic employees were identified as “active full time” or “part time”. During all the time periods assessed post diagnosis, a higher cumulative proportion of employees with metastasis had employment decrease vs. without metastases (month 1-3: 13% vs. 6%, month 4-6: 17% vs. 8%, month 7-12: 22% vs. 11%, full post diagnosis: 30% vs. 23%, all p<0.001). The median time to an employment decrease was significantly shorter for employees with metastatic vs. non-metastatic disease (4.3 vs. 14.7 months, p<0.001).

CONCLUSION: Cancers diagnosed at late stage are associated with higher likelihood and earlier onset of employment decrease than cancers diagnosed at early stage. Earlier detection of cancer may attenuate productivity loss and associated costs to employers and employees.

Code

HPR46

Topic

Health Policy & Regulatory

Topic Subcategory

Health Disparities & Equity, Insurance Systems & National Health Care, Public Spending & National Health Expenditures

Disease

No Additional Disease & Conditions/Specialized Treatment Areas